Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The FDA has granted clearance to Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding the company’s syndromic ...

Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. This marks Qiagen’s second ...

Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.

We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at ...

QIAGEN has filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON technology, specifically its Europea ...

Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...

Investment analysts at Zacks Research cut their Q1 2025 earnings per share estimates for Qiagen in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now expects ...

Shares of Qiagen (NYSE:QGEN – Get Free Report) have been assigned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, MarketBeat.com reports. Seven equities ...

Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company ...